Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Cironi, Luisa ^a   Provero, Paolo ^a   Riggi, Nicola ^a   Janiszewska, Michalina ^a   Suva, Domizio ^a   Suva, Mario Luca ^a   Kindler, Vincent ^a   Stamenkovic, Ivan ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN; PROTEIN BCL 2; SOMATOMEDIN B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SSX1; TRANSCRIPTION FACTOR SYT; TRANSCRIPTOME; TUMOR MARKER; UNCLASSIFIED DRUG; DNA; ONCOPROTEIN; SYT SSX FUSION PROTEIN; SYT-SSX FUSION PROTEIN;

ARTICLE; CELL ISOLATION; CELL POPULATION; CHROMATIN; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENOME IMPRINTING; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; METHYLATION; NUCLEOTIDE SEQUENCE; REPORTER GENE; SYNOVIAL SARCOMA; TRANSCRIPTION REGULATION; ADOLESCENT; ALLELE; CHILD; CONNECTIVE TISSUE TUMOR; CYTOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHYSIOLOGY;

ADOLESCENT; ALLELES; CHILD; CHROMATIN; CPG ISLANDS; DNA; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MESENCHYMAL STEM CELLS; ONCOGENE PROTEINS, FUSION; SARCOMA, SYNOVIAL; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 70949102042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007904     Document Type: Article

References (70)

1. Haldar M, Randall RL, Capecchi MR (2008) Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res 466: 2156-2167.
2. Sandberg AA, Bridge JA (2002) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet 133: 1-23.
3. Suva ML, Cironi L, Riggi N, Stamenkovic I (2007) Sarcomas: genetics, signalling, and cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase mutations. J Pathol 213: 117-130.
4. Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C, et al. (1997) The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 6: 1559-1564.
5. Lim FL, Soulez M, Koczan D, Thiesen HJ, Knight JC (1998) A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 17: 2013-2018.
6. Ishida M, Tanaka S, Ohki M, Ohta T (2004) Transcriptional co-activator activity of SYT is negatively regulated by BRM and Brg1. Genes Cells 9: 419-428.
7. PeraniM, Ingram CJ, Cooper CS, Garrett MD, Goodwin GH (2003) Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers. Oncogene 22: 8156-8167.
8. Thaete C, Brett D, Monaghan P, Whitehouse S, Rennie G, et al. (1999) Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet 8: 585-591.
9. Kato H, Tjernberg A, Zhang W, Krutchinsky AN, An W, et al. (2002) SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones. J Biol Chem 277: 5498-5505.
10. dos Santos NR, de Bruijn DR, van Kessel AG (2001) Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 30: 1-14.
11. de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, et al. (2006) The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 66: 9474-9482.
12. Hashimoto N, Araki N, Yoshikawa H, Myoui A, Matsumine A, et al. (2000) SYT-SSX fusion proteins in synovial sarcomas: detection and characterization with new antibodies. Cancer Lett 149: 31-36.
13. Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, et al. (2001) Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci U S A 98: 3843-3848.
14. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR (2007) A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 11: 375-388.
15. de Bruijn DR, dos Santos NR, Kater-Baats E, Thijssen J, van den Berk L, et al. (2002) The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes Chromosomes Cancer 34: 285-298.
16. de Bruijn DR, dos Santos NR, Thijssen J, Balemans M, Debernardi S, et al. (2001) The synovial sarcoma associated protein SYT interacts with the acute leukemia associated protein AF10. Oncogene 20: 3281-3289.
17. de Bruijn DR, van Dijk AH, Willemse MP, van Kessel AG (2008) The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4. Oncogene 27: 653-662.
18. Eid JE, Kung AL, Scully R, Livingston DM (2000) p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion. Cell 102: 839-848.
19. Ito T, Ouchida M, Ito S, Jitsumori Y, Morimoto Y, et al. (2004) SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. Lab Invest 84: 1484-1490.
20. Ito T, Ouchida M, Morimoto Y, Yoshida A, Jitsumori Y, et al. (2005) Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 224: 311-319.
21. Perani M, Antonson P, Hamoudi R, Ingram CJ, Cooper CS, et al. (2005) The proto-oncoprotein SYT interacts with SYT-interacting protein/ co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins. J Biol Chem 280: 42863-42876.
22. Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, et al. (2002) Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161: 1587-1595.
23. Francis P, Namlos HM, Muller C, Eden P, Fernebro J, et al. (2007) Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxiainduced transcription profile signifies metastatic potential. BMC Genomics 8: 73.
24. Tschoep K, Kohlmann A, Schlemmer M, Haferlach T, Issels RD (2007) Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63: 111-124.
25. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, et al. (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65: 9226-9235.
26. Bozzi F, Ferrari A, Negri T, Conca E, Luca da R, et al. (2008) Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation. Transl Oncol 1: 95-101.
27. de Bruijn DR, Nap JP, van Kessel AG (2007) The (epi)genetics of human synovial sarcoma. Genes Chromosomes Cancer 46: 107-117.
28. Friedrichs N, Kuchler J, Endl E, Koch A, Czerwitzki J, et al. (2008) Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 216: 428-439.
29. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT (2009) The insulin-like growth factor system and sarcomas. J Pathol 217: 469-482.
30. Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, et al. (2002) SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res 62: 3861-3867.
31. Xie Y, Skytting B, Nilsson G, Grimer RJ, Mangham CD, et al. (2002) The SYTSSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. Oncogene 21: 5791-5796.
32. Tsuda M, Watanabe T, Seki T, Kimura T, Sawa H, et al. (2005) Induction of p21(WAF1/CIP1) by human synovial sarcoma-associated chimeric oncoprotein SYT-SSX1. Oncogene 24: 7984-7990.
33. D'Arcy P, Maruwge W, Ryan BA, Brodin B (2008) The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. Mol Cancer Res 6: 127-138.
34. Pretto D, Barco R, Rivera J, Neel N, Gustavson MD, et al. (2006) The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene 25: 3661-3669.
35. Barco R, Hunt LB, Frump AL, Garcia CB, Benesh A, et al. (2007) The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. Mol Biol Cell 18: 4003-4012.
36. Ideraabdullah FY, Vigneau S, Bartolomei MS (2008) Genomic imprinting mechanisms in mammals. Mutat Res 647: 77-85.
37. Qiu X, Vu TH, Lu Q, Ling JQ, Li T, et al. (2008) A complex deoxyribonucleic acid looping configuration associated with the silencing of the maternal Igf2 allele. Mol Endocrinol 22: 1476-1488.
38. Zhao Z, Tavoosidana G, Sjolinder M, Gondor A, Mariano P, et al. (2006) Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- and interchromosomal interactions. Nat Genet 38: 1341-1347.
39. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, et al. (2006) IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 25: 1042-1052.
40. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, et al. (2008) Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 68: 4303-4310.
41. Suva D, Garavaglia G, Menetrey J, Chapuis B, Hoffmeyer P, et al. (2004) Nonhematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem cells. J Cell Physiol 198: 110-118.
42. Suva D, Passweg J, Arnaudeau S, Hoffmeyer P, Kindler V (2008) In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cell Physiol 214: 588-594.
43. Morison IM, Ramsay JP, Spencer HG (2005) A census of mammalian imprinting. Trends Genet 21: 457-465.
44. Gendler K, Paulsen T, Napoli C (2008) ChromDB: the chromatin database. Nucleic Acids Res 36: D298-302.
45. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
46. Wagner W, Feldmann RE Jr, Seckinger A, Maurer MH, Wein F, et al. (2006) The heterogeneity of human mesenchymal stem cell preparations-evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol 34: 536-548.
47. Wagner W, Ho AD (2007) Mesenchymal stem cell preparations-comparing apples and oranges. Stem Cell Rev 3: 239-248.
48. Antonescu CR, Kawai A, Leung DH, Lonardo F, Woodruff JM, et al. (2000) Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 9: 1-8.
49. Mancuso T, Mezzelani A, Riva C, Fabbri A, Dal Bo L, et al. (2000) Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest 80: 805-813.
50. Liu ZJ, Zhuge Y, Velazquez OC (2009) Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem.
51. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
52. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
53. Barco R, Garcia CB, Eid JE (2009) The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. PLoS One 4: e5060.
54. Monk D, Sanches R, Arnaud P, Apostolidou S, Hills FA, et al. (2006) Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet 15: 1259-1269.
55. Takai D, Gonzales FA, Tsai YC, Thayer MJ, Jones PA (2001) Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 10: 2619-2626.
56. Ulaner GA, Yang Y, Hu JF, Li T, Vu TH, et al. (2003) CTCF binding at the insulin-like growth factor-II (IGF2)/H19 imprinting control region is insufficient to regulate IGF2/H19 expression in human tissues. Endocrinology 144: 4420-4426.
57. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, et al. (2001) Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U S A 98: 591-596.
58. Ponce ML, Koelling S, Kluever A, Heinemann DE, Miosge N, et al. (2008) Coexpression of osteogenic and adipogenic differentiation markers in selected subpopulations of primary human mesenchymal progenitor cells. J Cell Biochem 104: 1342-1355.
59. Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, et al. (2002) Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 62: 5859-5866.
60. Kawai A, Kondo T, Suehara Y, Kikuta K, Hirohashi S (2008) Global proteinexpression analysis of bone and soft tissue sarcomas. Clin Orthop Relat Res 466: 2099-2106.
61. Rosa N, Samuel N, Lopez G, Antonio J, Carmen C, et al. (2004) A poorly differentiated synovial sarcoma (SYT/SSX1) expresses neuroectodermal markers: a xenografts and in vitro culture study. Diagn Mol Pathol 13: 52-59.
62. Bloushtain-Qimron N, Yao J, Shipitsin M, Maruyama R, Polyak K (2009) Epigenetic patterns of embryonic and adult stem cells. Cell Cycle 8.
63. Collas P (2008) Epigenetic states in stem cells. Biochim Biophys Acta.
64. Zardo G, Cimino G, Nervi C (2008) Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. Leukemia 22: 1503-1518.
65. Vu TH, Hoffman AR (1994) Promoter-specific imprinting of the human insulinlike growth factor-II gene. Nature 371: 714-717.
66. Ohlsson R, Hedborg F, Holmgren L, Walsh C, Ekstrom TJ (1994) Overlapping patterns of IGF2 and H19 expression during human development: biallelic IGF2 expression correlates with a lack of H19 expression. Development 120: 361-368.
67. Grbesa I, Ivkic M, Pegan B, Gall-Troselj K (2006) Loss of imprinting and promoter usage of the IGF2 in laryngeal squamous cell carcinoma. Cancer Lett 238: 224-229.
68. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
69. Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573: 83-92.
70. Shen L, Guo Y, Chen X, Ahmed S, Issa JP (2007) Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques 42: 48-50.